Next, on April 29, 2025, the company announced a long-term collaboration with Novo Nordisk starting with the immediate sale of "a bundled offering of Novo Nordisk's FDA-approved Wegovy® on the Hims & Hers platform." This news sent the price of Hims & Hers shares sharply higher during the next two weeks. Securities Class Actions Zero in on Company's Assurances and GLP-1 Strategy Legal actions filed in federal court allege that Hims & Hers issued repeated assurances to investors about its regulatory compliance, the robustness of revenue from its GLP-1 drug offerings, and the "tailwinds" presented by its collaboration with Novo Nordisk. Plaintiffs claim these assurances were misleading, contending that the company failed to disclose critical information about its business practices. Allegations of Deceptive Marketing and Patient Risk According to the complaints, Hims & Hers was engaged in what plaintiffs describe as the deceptive promotion and sale of unauthorized and knockoff versions of Wegovy®.